Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 700M | 0.7% |
| Gross Profit | 230M | 0.1% |
| Cost of Revenue | 556M | 19.5% |
| Operating expense | 101M | 3.6% |
| Net Income | 111M | 3.5% |
| EBITDA | 127M | 20.1% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 3.49B | 3.1% |
| Total Liabilities | 913M | 1% |
| Total Equity | 2.58B | 3.9% |
| Shares Outstanding | 73M | 0.5% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | 165M | 39.6% |
| Cash from investing | -101M | 11.7% |
| Cash from financing | -218M | 19.4% |
EPS
Financial Highlights for West Pharmaceutical Services in Q2 '24
West Pharmaceutical Services reported a revenue of 700M, which is a 0.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 230M, marking a -0.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 556M, a 19.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 101M, showing a -3.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 111M, showing a -3.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 127M, showing a -20.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
West Pharmaceutical Services faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures. A decline in EBITDA signals potential operational challenges or increased costs.